| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 89 | 2024 | 1903 | 14.660 |
Why?
|
| Retroperitoneal Neoplasms | 52 | 2024 | 341 | 13.430 |
Why?
|
| Gastrointestinal Stromal Tumors | 49 | 2024 | 652 | 9.600 |
Why?
|
| Soft Tissue Neoplasms | 31 | 2023 | 1370 | 6.560 |
Why?
|
| Gastrointestinal Neoplasms | 24 | 2024 | 1003 | 4.740 |
Why?
|
| Neoplasm Recurrence, Local | 52 | 2023 | 9305 | 3.090 |
Why?
|
| Liposarcoma | 18 | 2023 | 333 | 2.560 |
Why?
|
| Leiomyosarcoma | 18 | 2023 | 481 | 2.460 |
Why?
|
| Hemangiosarcoma | 9 | 2020 | 241 | 1.760 |
Why?
|
| Extremities | 11 | 2022 | 872 | 1.650 |
Why?
|
| Fibromatosis, Aggressive | 6 | 2021 | 123 | 1.630 |
Why?
|
| Nomograms | 6 | 2023 | 230 | 1.350 |
Why?
|
| Digestive System Surgical Procedures | 7 | 2016 | 581 | 1.140 |
Why?
|
| Antineoplastic Agents | 21 | 2024 | 13678 | 1.100 |
Why?
|
| Neoadjuvant Therapy | 16 | 2022 | 2775 | 1.040 |
Why?
|
| Combined Modality Therapy | 25 | 2022 | 8660 | 0.970 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 2019 | 555 | 0.960 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2023 | 621 | 0.930 |
Why?
|
| Piperazines | 9 | 2013 | 2502 | 0.870 |
Why?
|
| Rupture, Spontaneous | 2 | 2019 | 355 | 0.800 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2020 | 1775 | 0.800 |
Why?
|
| Pyrroles | 8 | 2012 | 1145 | 0.790 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2024 | 5584 | 0.770 |
Why?
|
| Pyrimidines | 9 | 2013 | 2987 | 0.770 |
Why?
|
| Nephrectomy | 3 | 2022 | 1046 | 0.760 |
Why?
|
| Prognosis | 42 | 2023 | 29264 | 0.760 |
Why?
|
| Not-For-Profit Insurance Plans | 1 | 2020 | 2 | 0.740 |
Why?
|
| United States Department of Defense | 1 | 2020 | 32 | 0.730 |
Why?
|
| Humans | 205 | 2024 | 752741 | 0.720 |
Why?
|
| Neoplasm Staging | 24 | 2022 | 11091 | 0.710 |
Why?
|
| Survival Rate | 26 | 2022 | 12802 | 0.710 |
Why?
|
| Indoles | 8 | 2012 | 1839 | 0.690 |
Why?
|
| Benzamides | 9 | 2013 | 1382 | 0.660 |
Why?
|
| Disease-Free Survival | 19 | 2023 | 6920 | 0.610 |
Why?
|
| Uterine Neoplasms | 5 | 2017 | 1505 | 0.600 |
Why?
|
| Postoperative Complications | 13 | 2022 | 15459 | 0.590 |
Why?
|
| Fibromatosis, Abdominal | 3 | 2012 | 24 | 0.570 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2020 | 3493 | 0.560 |
Why?
|
| Retrospective Studies | 53 | 2023 | 78758 | 0.560 |
Why?
|
| Radiotherapy | 5 | 2019 | 1533 | 0.560 |
Why?
|
| Pancreatic Neoplasms | 11 | 2019 | 5337 | 0.550 |
Why?
|
| Stomach Neoplasms | 5 | 2022 | 1356 | 0.520 |
Why?
|
| Proto-Oncogene Proteins c-kit | 6 | 2024 | 782 | 0.510 |
Why?
|
| Rosaniline Dyes | 2 | 2005 | 51 | 0.500 |
Why?
|
| Middle Aged | 81 | 2024 | 216054 | 0.500 |
Why?
|
| Polymers | 3 | 2023 | 1625 | 0.500 |
Why?
|
| Adrenal Glands | 1 | 2017 | 557 | 0.500 |
Why?
|
| Aged | 71 | 2024 | 165629 | 0.480 |
Why?
|
| Solitary Fibrous Tumors | 3 | 2020 | 74 | 0.480 |
Why?
|
| Neoplasm Invasiveness | 7 | 2017 | 3627 | 0.470 |
Why?
|
| Postoperative Care | 2 | 2019 | 1497 | 0.450 |
Why?
|
| Neoplasms, Second Primary | 2 | 2012 | 1073 | 0.440 |
Why?
|
| Neoplasm Metastasis | 9 | 2020 | 4881 | 0.430 |
Why?
|
| Brachytherapy | 4 | 2014 | 1247 | 0.430 |
Why?
|
| Paclitaxel | 4 | 2023 | 1708 | 0.430 |
Why?
|
| Adult | 72 | 2024 | 216658 | 0.420 |
Why?
|
| Female | 99 | 2024 | 385090 | 0.420 |
Why?
|
| Pancreaticoduodenectomy | 4 | 2018 | 507 | 0.420 |
Why?
|
| Pancreatectomy | 4 | 2021 | 819 | 0.410 |
Why?
|
| Breast Neoplasms | 12 | 2022 | 20914 | 0.410 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2017 | 934 | 0.410 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2018 | 2450 | 0.400 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 258 | 0.400 |
Why?
|
| Limb Salvage | 3 | 2011 | 444 | 0.400 |
Why?
|
| Gastrectomy | 2 | 2014 | 669 | 0.390 |
Why?
|
| Benzenesulfonates | 1 | 2012 | 169 | 0.390 |
Why?
|
| Aged, 80 and over | 33 | 2023 | 58361 | 0.390 |
Why?
|
| Iodine Radioisotopes | 1 | 2014 | 1035 | 0.380 |
Why?
|
| Databases, Factual | 5 | 2020 | 7805 | 0.370 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 877 | 0.370 |
Why?
|
| Extracellular Fluid | 1 | 2012 | 171 | 0.370 |
Why?
|
| Skin Neoplasms | 5 | 2022 | 5751 | 0.370 |
Why?
|
| Therapies, Investigational | 1 | 2011 | 114 | 0.370 |
Why?
|
| SEER Program | 6 | 2019 | 1510 | 0.370 |
Why?
|
| Markov Chains | 1 | 2013 | 979 | 0.360 |
Why?
|
| Laparoscopy | 2 | 2020 | 2145 | 0.350 |
Why?
|
| Male | 79 | 2024 | 354311 | 0.350 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 39223 | 0.340 |
Why?
|
| Colon | 1 | 2017 | 1800 | 0.340 |
Why?
|
| Intestinal Neoplasms | 1 | 2012 | 320 | 0.340 |
Why?
|
| Survival Analysis | 11 | 2020 | 10252 | 0.340 |
Why?
|
| Population Surveillance | 2 | 2019 | 2618 | 0.330 |
Why?
|
| Molecular Targeted Therapy | 4 | 2020 | 2755 | 0.330 |
Why?
|
| Chondrosarcoma | 1 | 2011 | 308 | 0.330 |
Why?
|
| Heart Neoplasms | 1 | 2012 | 368 | 0.320 |
Why?
|
| Disease Management | 2 | 2016 | 2473 | 0.320 |
Why?
|
| Salvage Therapy | 2 | 2012 | 1279 | 0.310 |
Why?
|
| Lipoma | 2 | 2017 | 328 | 0.310 |
Why?
|
| Hysterectomy | 2 | 2014 | 945 | 0.310 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2008 | 63 | 0.300 |
Why?
|
| Physician Incentive Plans | 1 | 2009 | 161 | 0.300 |
Why?
|
| Treatment Outcome | 26 | 2024 | 64017 | 0.300 |
Why?
|
| Medical Oncology | 2 | 2021 | 2298 | 0.300 |
Why?
|
| Anaphylaxis | 2 | 2005 | 748 | 0.300 |
Why?
|
| Sciatic Neuropathy | 1 | 2007 | 75 | 0.280 |
Why?
|
| Delivery, Obstetric | 1 | 2014 | 949 | 0.280 |
Why?
|
| Fasciitis | 1 | 2007 | 66 | 0.280 |
Why?
|
| Neoplasms | 5 | 2024 | 21976 | 0.270 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 3069 | 0.270 |
Why?
|
| Vascular Neoplasms | 1 | 2007 | 178 | 0.260 |
Why?
|
| Pancreas | 2 | 2022 | 1704 | 0.260 |
Why?
|
| Intestine, Small | 1 | 2012 | 1244 | 0.260 |
Why?
|
| Surgical Procedures, Operative | 2 | 2016 | 1890 | 0.260 |
Why?
|
| Decision Making | 2 | 2017 | 3909 | 0.260 |
Why?
|
| Microsatellite Repeats | 2 | 2004 | 801 | 0.260 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2022 | 709 | 0.260 |
Why?
|
| Histamine H1 Antagonists | 1 | 2005 | 101 | 0.260 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 3111 | 0.260 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2019 | 6542 | 0.250 |
Why?
|
| Neuroendocrine Tumors | 1 | 2011 | 607 | 0.250 |
Why?
|
| Carcinoid Tumor | 1 | 2006 | 233 | 0.250 |
Why?
|
| Interleukin-8 | 2 | 2004 | 695 | 0.240 |
Why?
|
| Incidence | 10 | 2021 | 21146 | 0.240 |
Why?
|
| Adenocarcinoma | 5 | 2019 | 6387 | 0.240 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2004 | 46 | 0.240 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 3218 | 0.240 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 445 | 0.240 |
Why?
|
| Endostatins | 1 | 2004 | 174 | 0.230 |
Why?
|
| Insulinoma | 1 | 2004 | 123 | 0.230 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 4280 | 0.230 |
Why?
|
| Tumor Burden | 5 | 2017 | 1917 | 0.230 |
Why?
|
| Retroperitoneal Space | 2 | 2022 | 183 | 0.230 |
Why?
|
| Mastectomy, Segmental | 3 | 2017 | 954 | 0.230 |
Why?
|
| Comprehension | 1 | 2009 | 617 | 0.230 |
Why?
|
| Length of Stay | 3 | 2022 | 6355 | 0.230 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2023 | 67 | 0.230 |
Why?
|
| Naphthyridines | 1 | 2024 | 121 | 0.220 |
Why?
|
| Risk Factors | 13 | 2022 | 73094 | 0.220 |
Why?
|
| Rare Diseases | 3 | 2021 | 605 | 0.220 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2008 | 517 | 0.220 |
Why?
|
| Hyperparathyroidism | 1 | 2004 | 340 | 0.220 |
Why?
|
| Parathyroid Neoplasms | 1 | 2004 | 245 | 0.220 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 368 | 0.220 |
Why?
|
| Duodenal Neoplasms | 2 | 2013 | 106 | 0.210 |
Why?
|
| Apoptosis | 6 | 2022 | 9657 | 0.210 |
Why?
|
| Ganglioneuroma | 1 | 2022 | 57 | 0.210 |
Why?
|
| Pheochromocytoma | 1 | 2004 | 333 | 0.200 |
Why?
|
| Pelvic Neoplasms | 1 | 2024 | 257 | 0.200 |
Why?
|
| Kidney | 1 | 2017 | 7152 | 0.200 |
Why?
|
| Age Factors | 4 | 2022 | 18460 | 0.200 |
Why?
|
| Young Adult | 18 | 2021 | 57267 | 0.200 |
Why?
|
| Mice, Nude | 6 | 2019 | 3668 | 0.200 |
Why?
|
| Urea | 1 | 2024 | 448 | 0.200 |
Why?
|
| Succinate Dehydrogenase | 2 | 2019 | 146 | 0.200 |
Why?
|
| Biopsy, Needle | 2 | 2006 | 1642 | 0.200 |
Why?
|
| General Surgery | 2 | 2012 | 1645 | 0.200 |
Why?
|
| Pyridines | 2 | 2019 | 2841 | 0.190 |
Why?
|
| Models, Economic | 2 | 2017 | 711 | 0.190 |
Why?
|
| Popliteal Artery | 1 | 2003 | 322 | 0.190 |
Why?
|
| Phyllodes Tumor | 1 | 2021 | 53 | 0.190 |
Why?
|
| Doxorubicin | 3 | 2022 | 2242 | 0.190 |
Why?
|
| Fellowships and Scholarships | 2 | 2020 | 1101 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 17635 | 0.190 |
Why?
|
| Biological Products | 2 | 2022 | 881 | 0.190 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2021 | 58 | 0.190 |
Why?
|
| Nevus, Blue | 1 | 2020 | 43 | 0.180 |
Why?
|
| Carcinoma, Papillary | 1 | 2006 | 792 | 0.180 |
Why?
|
| Risk Assessment | 5 | 2017 | 23554 | 0.180 |
Why?
|
| Tropomyosin | 1 | 2020 | 102 | 0.180 |
Why?
|
| Genomic Instability | 1 | 2004 | 706 | 0.180 |
Why?
|
| Aneurysm | 1 | 2003 | 340 | 0.180 |
Why?
|
| Diagnostic Imaging | 3 | 2011 | 3511 | 0.180 |
Why?
|
| Hemangiopericytoma | 1 | 2020 | 79 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2019 | 11626 | 0.180 |
Why?
|
| Mitotic Index | 3 | 2020 | 172 | 0.180 |
Why?
|
| Endosonography | 2 | 2008 | 611 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 3 | 2005 | 2654 | 0.180 |
Why?
|
| Renal Replacement Therapy | 1 | 2022 | 245 | 0.180 |
Why?
|
| Hodgkin Disease | 1 | 2007 | 1417 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2021 | 10057 | 0.160 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2004 | 742 | 0.160 |
Why?
|
| Pathology, Clinical | 1 | 2022 | 375 | 0.160 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 105 | 0.160 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 2761 | 0.160 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2018 | 111 | 0.160 |
Why?
|
| Bone Neoplasms | 2 | 2021 | 2546 | 0.160 |
Why?
|
| Consensus | 7 | 2022 | 3023 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 7355 | 0.160 |
Why?
|
| Splenectomy | 2 | 2018 | 395 | 0.160 |
Why?
|
| Videoconferencing | 1 | 2020 | 200 | 0.150 |
Why?
|
| Abdomen | 2 | 2022 | 1125 | 0.150 |
Why?
|
| Neoplasm, Residual | 4 | 2017 | 984 | 0.150 |
Why?
|
| Mutation | 10 | 2024 | 29981 | 0.150 |
Why?
|
| Oncogenes | 2 | 2020 | 1259 | 0.140 |
Why?
|
| Quality of Life | 1 | 2018 | 13044 | 0.140 |
Why?
|
| Mice | 12 | 2023 | 81766 | 0.140 |
Why?
|
| North America | 2 | 2020 | 1255 | 0.140 |
Why?
|
| Upper Extremity | 2 | 2012 | 656 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2008 | 1856 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2020 | 482 | 0.140 |
Why?
|
| Europe | 3 | 2020 | 3359 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 3572 | 0.140 |
Why?
|
| Uterus | 1 | 2020 | 695 | 0.140 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 2957 | 0.130 |
Why?
|
| Glucocorticoids | 1 | 2005 | 2129 | 0.130 |
Why?
|
| Poland | 1 | 2016 | 184 | 0.130 |
Why?
|
| London | 1 | 2016 | 234 | 0.130 |
Why?
|
| Vascular Surgical Procedures | 2 | 2004 | 1478 | 0.130 |
Why?
|
| Adrenalectomy | 1 | 2017 | 342 | 0.130 |
Why?
|
| Disease Progression | 8 | 2022 | 13364 | 0.130 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2015 | 41 | 0.130 |
Why?
|
| History, 19th Century | 1 | 2017 | 722 | 0.130 |
Why?
|
| Ontario | 1 | 2016 | 386 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 3 | 2011 | 6233 | 0.130 |
Why?
|
| Endothelial Cells | 2 | 2004 | 3518 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2004 | 1963 | 0.120 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 726 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2005 | 1902 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 308 | 0.120 |
Why?
|
| Catheter Ablation | 2 | 2005 | 2768 | 0.120 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2006 | 1696 | 0.120 |
Why?
|
| Cell Line, Tumor | 5 | 2023 | 16789 | 0.120 |
Why?
|
| Morbidity | 4 | 2021 | 1784 | 0.120 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 77 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2023 | 20346 | 0.120 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 6624 | 0.120 |
Why?
|
| Time Factors | 10 | 2019 | 40195 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2004 | 1993 | 0.120 |
Why?
|
| Neuroblastoma | 1 | 2022 | 1242 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 2160 | 0.120 |
Why?
|
| Carcinoma, Small Cell | 1 | 2016 | 419 | 0.120 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 18174 | 0.120 |
Why?
|
| Adolescent | 14 | 2021 | 86713 | 0.120 |
Why?
|
| Italy | 2 | 2014 | 831 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 708 | 0.120 |
Why?
|
| Biopsy | 3 | 2022 | 6771 | 0.120 |
Why?
|
| Animals | 15 | 2024 | 169600 | 0.110 |
Why?
|
| Germany | 1 | 2016 | 873 | 0.110 |
Why?
|
| Phenylurea Compounds | 2 | 2019 | 527 | 0.110 |
Why?
|
| Fibrosarcoma | 2 | 2017 | 348 | 0.110 |
Why?
|
| Interviews as Topic | 1 | 2020 | 2580 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2018 | 866 | 0.110 |
Why?
|
| Radiotherapy Dosage | 5 | 2015 | 2893 | 0.110 |
Why?
|
| Organs at Risk | 1 | 2015 | 356 | 0.110 |
Why?
|
| Skin | 2 | 2019 | 4393 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 1806 | 0.110 |
Why?
|
| Genital Neoplasms, Male | 1 | 2013 | 74 | 0.110 |
Why?
|
| Professional Role | 1 | 2015 | 312 | 0.110 |
Why?
|
| Dystrophin | 1 | 2014 | 290 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 2259 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 5410 | 0.110 |
Why?
|
| Career Choice | 1 | 2019 | 751 | 0.110 |
Why?
|
| Hospitals | 2 | 2022 | 3986 | 0.100 |
Why?
|
| Mediator Complex | 1 | 2012 | 109 | 0.100 |
Why?
|
| Music | 1 | 2015 | 271 | 0.100 |
Why?
|
| Liver Neoplasms | 2 | 2005 | 4311 | 0.100 |
Why?
|
| Smooth Muscle Tumor | 1 | 2012 | 67 | 0.100 |
Why?
|
| Colectomy | 1 | 2017 | 694 | 0.100 |
Why?
|
| Iodide Peroxidase | 1 | 2014 | 297 | 0.100 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2004 | 599 | 0.100 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2008 | 1110 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2019 | 1189 | 0.100 |
Why?
|
| Proportional Hazards Models | 5 | 2022 | 12423 | 0.100 |
Why?
|
| Prospective Studies | 9 | 2022 | 53863 | 0.100 |
Why?
|
| Rectum | 1 | 2016 | 907 | 0.100 |
Why?
|
| Muscular Dystrophies | 1 | 2014 | 393 | 0.100 |
Why?
|
| International Cooperation | 2 | 2021 | 1439 | 0.100 |
Why?
|
| Angiogenic Proteins | 1 | 2012 | 104 | 0.100 |
Why?
|
| Preoperative Care | 4 | 2015 | 2258 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 901 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2017 | 1552 | 0.100 |
Why?
|
| Thyroid Hormones | 1 | 2014 | 392 | 0.100 |
Why?
|
| Medical Staff, Hospital | 1 | 2015 | 606 | 0.100 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2011 | 91 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2014 | 599 | 0.100 |
Why?
|
| Netherlands | 1 | 2016 | 2175 | 0.100 |
Why?
|
| Meningeal Neoplasms | 1 | 2020 | 1249 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 2888 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2019 | 1160 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 1143 | 0.090 |
Why?
|
| Physicians | 1 | 2009 | 4625 | 0.090 |
Why?
|
| Carcinoma | 1 | 2022 | 2385 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2008 | 5469 | 0.090 |
Why?
|
| Patient Participation | 1 | 2020 | 1464 | 0.090 |
Why?
|
| United States | 8 | 2020 | 70772 | 0.090 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 9431 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 2 | 2008 | 678 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2012 | 766 | 0.090 |
Why?
|
| DNA Mutational Analysis | 5 | 2020 | 4179 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2023 | 35798 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2016 | 2978 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2020 | 543 | 0.090 |
Why?
|
| Niacinamide | 1 | 2012 | 417 | 0.090 |
Why?
|
| Safety | 1 | 2014 | 1179 | 0.090 |
Why?
|
| Connective Tissue | 2 | 2022 | 424 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2017 | 2766 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2019 | 1354 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 5199 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 2940 | 0.080 |
Why?
|
| Radiation Oncology | 1 | 2015 | 556 | 0.080 |
Why?
|
| Operating Rooms | 1 | 2015 | 822 | 0.080 |
Why?
|
| Pleural Neoplasms | 1 | 2014 | 615 | 0.080 |
Why?
|
| Hypothyroidism | 1 | 2014 | 670 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2013 | 603 | 0.080 |
Why?
|
| Pressure | 1 | 2012 | 1207 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2024 | 4526 | 0.080 |
Why?
|
| Patient Preference | 1 | 2015 | 899 | 0.080 |
Why?
|
| Capillary Permeability | 1 | 2012 | 805 | 0.080 |
Why?
|
| Base Pair Mismatch | 2 | 2004 | 97 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2004 | 6855 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2011 | 422 | 0.080 |
Why?
|
| Mesentery | 1 | 2008 | 205 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 2191 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 12250 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 10914 | 0.080 |
Why?
|
| Rectal Neoplasms | 1 | 2016 | 1190 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2019 | 10508 | 0.070 |
Why?
|
| Lower Extremity | 2 | 2012 | 1189 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 1041 | 0.070 |
Why?
|
| Skin Transplantation | 1 | 2012 | 1080 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2014 | 1217 | 0.070 |
Why?
|
| Paraganglioma | 1 | 2009 | 143 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 1185 | 0.070 |
Why?
|
| Registries | 2 | 2022 | 8216 | 0.070 |
Why?
|
| Leiomyoma | 1 | 2012 | 720 | 0.070 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2009 | 124 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2014 | 1547 | 0.070 |
Why?
|
| Estrogens | 1 | 2014 | 1573 | 0.070 |
Why?
|
| Video Recording | 1 | 2012 | 953 | 0.070 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 2006 | 31 | 0.070 |
Why?
|
| Genomics | 2 | 2020 | 5743 | 0.070 |
Why?
|
| Contrast Media | 4 | 2014 | 5338 | 0.070 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2006 | 57 | 0.070 |
Why?
|
| Lymph Nodes | 2 | 2022 | 3503 | 0.070 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 1648 | 0.070 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 844 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2014 | 2642 | 0.070 |
Why?
|
| Pancreatic Diseases | 1 | 2008 | 349 | 0.070 |
Why?
|
| Efficiency | 1 | 2009 | 468 | 0.070 |
Why?
|
| Laparotomy | 1 | 2008 | 471 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2018 | 379 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2022 | 4579 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2012 | 1356 | 0.060 |
Why?
|
| Immunohistochemistry | 4 | 2020 | 11395 | 0.060 |
Why?
|
| Group IV Phospholipases A2 | 1 | 2004 | 59 | 0.060 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2012 | 1096 | 0.060 |
Why?
|
| Phospholipases A2 | 1 | 2004 | 203 | 0.060 |
Why?
|
| Mesenteric Veins | 1 | 2004 | 86 | 0.060 |
Why?
|
| Pancreatic Cyst | 1 | 2008 | 368 | 0.060 |
Why?
|
| Cohort Studies | 6 | 2017 | 40939 | 0.060 |
Why?
|
| DNA Sequence, Unstable | 1 | 2004 | 1 | 0.060 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2004 | 66 | 0.060 |
Why?
|
| Indomethacin | 1 | 2004 | 331 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2004 | 216 | 0.060 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 3652 | 0.060 |
Why?
|
| Mastectomy | 1 | 2012 | 1814 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2012 | 1662 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 328 | 0.060 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 13042 | 0.060 |
Why?
|
| Positron-Emission Tomography | 3 | 2013 | 6364 | 0.060 |
Why?
|
| Proteins | 1 | 2019 | 6093 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2014 | 2854 | 0.060 |
Why?
|
| Canada | 2 | 2020 | 2081 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 1984 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2004 | 3512 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2019 | 4729 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2012 | 5144 | 0.050 |
Why?
|
| Boston | 1 | 2016 | 9348 | 0.050 |
Why?
|
| Acute Disease | 2 | 2015 | 7221 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 2492 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2004 | 319 | 0.050 |
Why?
|
| Intraoperative Care | 1 | 2006 | 764 | 0.050 |
Why?
|
| Prevalence | 1 | 2019 | 15404 | 0.050 |
Why?
|
| Propensity Score | 2 | 2020 | 1828 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3136 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2022 | 191 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 612 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3246 | 0.050 |
Why?
|
| Portal Vein | 1 | 2004 | 435 | 0.050 |
Why?
|
| Melanoma | 1 | 2020 | 5547 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 13263 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2004 | 600 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2009 | 15164 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3871 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2004 | 501 | 0.050 |
Why?
|
| Wound Healing | 1 | 2012 | 2798 | 0.050 |
Why?
|
| Ultrasonography, Mammary | 2 | 2014 | 248 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 1798 | 0.050 |
Why?
|
| Triazoles | 2 | 2019 | 909 | 0.050 |
Why?
|
| MART-1 Antigen | 1 | 2020 | 66 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 3700 | 0.050 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2020 | 25 | 0.050 |
Why?
|
| Inflammation | 1 | 2020 | 10751 | 0.050 |
Why?
|
| Sensitivity and Specificity | 4 | 2018 | 14761 | 0.040 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 2019 | 27 | 0.040 |
Why?
|
| DNA Methylation | 3 | 2019 | 4315 | 0.040 |
Why?
|
| Pancreatic Fistula | 1 | 2021 | 146 | 0.040 |
Why?
|
| Biology | 1 | 2022 | 294 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8607 | 0.040 |
Why?
|
| S100 Proteins | 1 | 2020 | 261 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2022 | 334 | 0.040 |
Why?
|
| Receptor, trkA | 1 | 2020 | 165 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2011 | 1944 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2005 | 1463 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2018 | 1848 | 0.040 |
Why?
|
| Authorship | 1 | 2022 | 277 | 0.040 |
Why?
|
| Radiopharmaceuticals | 2 | 2013 | 2675 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2019 | 4228 | 0.040 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2019 | 184 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2021 | 356 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 553 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2019 | 5858 | 0.040 |
Why?
|
| Nevus, Pigmented | 1 | 2020 | 220 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2018 | 12165 | 0.040 |
Why?
|
| Personnel Selection | 1 | 2020 | 190 | 0.040 |
Why?
|
| DNA Repair | 2 | 2004 | 2058 | 0.040 |
Why?
|
| Research Design | 1 | 2014 | 6118 | 0.040 |
Why?
|
| Observer Variation | 2 | 2015 | 2622 | 0.040 |
Why?
|
| Omentum | 1 | 2019 | 171 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 4943 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2014 | 11553 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 2936 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2006 | 1517 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2024 | 2015 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2020 | 455 | 0.040 |
Why?
|
| Gene Expression | 2 | 2022 | 7771 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1690 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2020 | 371 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2020 | 6352 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 850 | 0.040 |
Why?
|
| Melanocytes | 1 | 2020 | 515 | 0.040 |
Why?
|
| Risk | 1 | 2009 | 9683 | 0.040 |
Why?
|
| Cricetulus | 1 | 2019 | 821 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2020 | 552 | 0.040 |
Why?
|
| Azepines | 1 | 2019 | 333 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2017 | 287 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 630 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2020 | 2633 | 0.030 |
Why?
|
| CHO Cells | 1 | 2019 | 1410 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2017 | 2967 | 0.030 |
Why?
|
| Carboplatin | 1 | 2019 | 802 | 0.030 |
Why?
|
| Benchmarking | 1 | 2022 | 1048 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 2223 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 884 | 0.030 |
Why?
|
| Neurofibromin 1 | 1 | 2017 | 195 | 0.030 |
Why?
|
| Infarction | 1 | 2017 | 250 | 0.030 |
Why?
|
| Gene Silencing | 2 | 2017 | 1543 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 2087 | 0.030 |
Why?
|
| Texas | 2 | 2007 | 395 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 2287 | 0.030 |
Why?
|
| Interstitial Cells of Cajal | 1 | 2014 | 25 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2012 | 5149 | 0.030 |
Why?
|
| Health Resources | 1 | 2020 | 920 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 2019 | 0.030 |
Why?
|
| Salpingectomy | 1 | 2014 | 53 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 1364 | 0.030 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 1994 | 131 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 11909 | 0.030 |
Why?
|
| Program Development | 1 | 2020 | 1314 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 529 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2019 | 881 | 0.030 |
Why?
|
| Data Collection | 1 | 2022 | 3350 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 1343 | 0.030 |
Why?
|
| Necrosis | 1 | 2017 | 1641 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2024 | 2229 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 1579 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 4459 | 0.030 |
Why?
|
| Muscle Development | 1 | 2014 | 269 | 0.030 |
Why?
|
| Mammography | 2 | 2014 | 2459 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2017 | 1400 | 0.030 |
Why?
|
| Pregnancy | 1 | 2014 | 29630 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 1127 | 0.030 |
Why?
|
| Employment | 1 | 2019 | 1140 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 796 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2020 | 1187 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2014 | 665 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 414 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2014 | 798 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 1 | 2014 | 387 | 0.020 |
Why?
|
| Multigene Family | 1 | 1994 | 1101 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 1700 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 15657 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 539 | 0.020 |
Why?
|
| X Chromosome | 1 | 1994 | 819 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 1666 | 0.020 |
Why?
|
| Duodenum | 1 | 2013 | 487 | 0.020 |
Why?
|
| Learning Curve | 1 | 2012 | 208 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 2846 | 0.020 |
Why?
|
| Aromatase Inhibitors | 1 | 2014 | 511 | 0.020 |
Why?
|
| Fibrosis | 1 | 2017 | 2028 | 0.020 |
Why?
|
| Lymphoma | 1 | 2019 | 1892 | 0.020 |
Why?
|
| Kidney Calculi | 1 | 1994 | 468 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 1096 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 2945 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 1019 | 0.020 |
Why?
|
| Cystadenoma, Papillary | 1 | 2008 | 7 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2011 | 759 | 0.020 |
Why?
|
| Nitriles | 1 | 2014 | 960 | 0.020 |
Why?
|
| Patient Selection | 1 | 2021 | 4232 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2013 | 886 | 0.020 |
Why?
|
| Eye Diseases | 1 | 1994 | 673 | 0.020 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2008 | 61 | 0.020 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2008 | 84 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3605 | 0.020 |
Why?
|
| Catecholamines | 1 | 2009 | 387 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2009 | 517 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 2606 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 3885 | 0.020 |
Why?
|
| Gastroenterostomy | 1 | 2007 | 18 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2004 | 7941 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2022 | 9223 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2011 | 499 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 8971 | 0.020 |
Why?
|
| Vinblastine | 1 | 2008 | 503 | 0.020 |
Why?
|
| Cell Survival | 1 | 2017 | 5860 | 0.020 |
Why?
|
| Genome, Human | 1 | 2020 | 4446 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 813 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 3686 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 2746 | 0.020 |
Why?
|
| Triiodobenzoic Acids | 1 | 2006 | 124 | 0.020 |
Why?
|
| Menopause | 1 | 2014 | 1641 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 2812 | 0.020 |
Why?
|
| Breast | 1 | 2014 | 1973 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 3901 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 3674 | 0.020 |
Why?
|
| Attention | 1 | 2015 | 2398 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 6417 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2007 | 500 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 7970 | 0.020 |
Why?
|
| Adipocytes | 1 | 2011 | 1193 | 0.020 |
Why?
|
| Propionates | 1 | 2005 | 170 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2008 | 332 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2015 | 2555 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 2033 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2005 | 190 | 0.010 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2004 | 85 | 0.010 |
Why?
|
| Child | 3 | 2021 | 78594 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 5222 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2007 | 345 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 1235 | 0.010 |
Why?
|
| Advisory Committees | 1 | 2007 | 779 | 0.010 |
Why?
|
| Radiography | 1 | 2014 | 7047 | 0.010 |
Why?
|
| Age Distribution | 1 | 2008 | 2905 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 2101 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2007 | 1183 | 0.010 |
Why?
|
| Cell Movement | 1 | 2014 | 5222 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 2927 | 0.010 |
Why?
|
| Reoperation | 1 | 2011 | 4248 | 0.010 |
Why?
|
| Genes, ras | 1 | 2004 | 689 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 1281 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 20026 | 0.010 |
Why?
|
| Zebrafish | 1 | 2011 | 3000 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 4929 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2012 | 8413 | 0.010 |
Why?
|
| ROC Curve | 1 | 2006 | 3558 | 0.010 |
Why?
|
| Nurses | 1 | 2007 | 2476 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 2387 | 0.010 |
Why?
|
| Smoking | 1 | 2013 | 9030 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 11211 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2004 | 1411 | 0.010 |
Why?
|
| Cosmids | 1 | 1994 | 106 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 25454 | 0.010 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 1994 | 116 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 15657 | 0.010 |
Why?
|
| Algorithms | 1 | 2015 | 13984 | 0.010 |
Why?
|
| Night Blindness | 1 | 1994 | 53 | 0.010 |
Why?
|
| Dinucleoside Phosphates | 1 | 1994 | 78 | 0.010 |
Why?
|
| Critical Care | 1 | 2007 | 2696 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 8414 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2007 | 5367 | 0.010 |
Why?
|
| Synovial Membrane | 1 | 1994 | 518 | 0.010 |
Why?
|
| Retinitis Pigmentosa | 1 | 1994 | 391 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 13441 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 2880 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 25903 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 1994 | 1410 | 0.000 |
Why?
|
| Infant | 1 | 2009 | 35447 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2009 | 41390 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2004 | 21904 | 0.000 |
Why?
|
| Phenotype | 1 | 2004 | 16484 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1994 | 4723 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1994 | 6169 | 0.000 |
Why?
|
| Base Sequence | 1 | 1994 | 12769 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 18050 | 0.000 |
Why?
|